Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir monotherapy versus favipiravir + camostat + inhaled ciclesonide for COVID-19 pneumonia
jRCTs031200196Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia comparing Favipiravir monotherapy with Favipiravir + camostat mesilate + inhaled ciclesonide (2 arms). Primary endpoint: Length of hospital stay. Started Nov 2020; status: completed.
02
Drugs
favipiravircamostat mesilateciclesonide
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on jRCTs031200196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200196.